The
advent of CRISPR-Cas9 gene-editing technology has sparked a complex discourse
on diversity, equity, and inclusion (DEI). While it could potentially eradicate
genetic disorders affecting marginalized groups, concerns arise regarding
ethical implications, eugenics, exacerbating biases, and socioeconomic divides.
One salient aspect of this discourse pertains to the ethical considerations
surrounding using CRISPR-Cas9 for germline editing, which could theoretically
eradicate genetic disorders disproportionately affecting specific populations.
Proponents argue it could foster inclusivity through personalized therapies for
underrepresented populations, though met with skepticism. This revolutionary
tool necessitates critically examining its ethical, socioeconomic, and
governance ramifications.
